Advertisement
Advertisement
SNOA
Sonoma Pharmaceuticals, Inc. Common Stock
1.29
USDSponsored
-0.15
-10.42%
Aug 10, 15:59 UTC -4
Closed
After-Market
1.32
+0.03
+2.02%
SNOA Earnings Reports
Positive Surprise Ratio
SNOA beat 11 of 21 last estimates.
52%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q2 27 (Revenue/ EPS)
$5.39M
/-$0.10
Implied change from Q1 27 (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
-3.77%
/-68.75%
Sonoma Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, SNOA reported earnings of -- USD per share (EPS) for Q1 27, -- the estimate of -0.30 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 5.09 million, with a --% difference.
Looking ahead to Q2 27, 3 analysts forecast an EPS of -0.10 USD, with revenue projected to reach 5.39 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
Nature's Sunshine Products Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.27
Actual
$0.21
Surprise
-23.75%
Tonix Pharmaceuticals Holding Corp.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.75
Actual
-$2.44
Surprise
+11.29%
Fractyl Health, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+12.85%
FAQ
What were Sonoma Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2027?
For Q1 2027, Sonoma Pharmaceuticals, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Sonoma Pharmaceuticals, Inc. Common Stock's Q1 2027 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Sonoma Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Sonoma Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 3
analysts, Sonoma Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.10 and revenue of $5.39M for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement